• Je něco špatně v tomto záznamu ?

Increased Donor-Derived Cell-Free DNA as a Predictor for the Early Detection of Antibody-Mediated Rejection Following Heart Transplantation

D. Dlouha, S. Chytilova, J. Vymetalova, E. Rohlova, M. Lukasova, S. Novakova, JA. Hubacek

. 2025 ; 39 (6) : e70209. [pub] -

Jazyk angličtina Země Dánsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015408

Grantová podpora
NU20-06-00061 the Ministry of Health of the Czech Republic
the Ministry of Health of the Czech Republic-DRO
IN 00023001 Institute for Clinical and Experimental Medicine-IKEM

Plasma circulating donor-derived cell-free DNA (ddcfDNA) can be used to noninvasively monitor acute rejection of heart transplants (HTx). This study utilized digital droplet PCR to analyze ddcfDNA concentrations (measured in copies per milliliter) and the fractional abundance (%ddcfDNA) to differentiate between donor and recipient DNA on the basis of single nucleotide polymorphism (SNP) homozygosity. Seventy-seven patients participated in a study, providing 300 plasma samples. Both markers, mean ddcfDNA (cp/mL) and %ddcfDNA, showed similar decreasing trends following the HTx, (R2 < 0.2; p < 0.001). Significantly higher levels of ddcfDNA (cp/mL) and %ddcfDNA were observed during episodes of acute rejection (AR) compared to non-rejection samples (p < 0.001). Additionally, antibody-mediated rejection (AMR) was associated with increased %ddcfDNA levels compared to non-rejection and to acute cellular rejection samples (p < 0.001 and p < 0.01). A logistic regression model identified %ddcfDNA as an early predictor of AMR risk 10-19 days post-heart transplant (odds ratio 158, p < 0.02). Performance analysis established an optimal %ddcfDNA threshold of 0.125% for AMR detection, correctly identifying all patients without subsequent AMR. These findings suggest that early %ddcfDNA measurements post-HTx can accurately identify individuals unlikely to develop AMR during the first posttransplant year.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015408
003      
CZ-PrNML
005      
20250731090947.0
007      
ta
008      
250708s2025 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ctr.70209 $2 doi
035    __
$a (PubMed)40478999
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Dlouha, Dana $u Experimental Medicine Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000171671336
245    10
$a Increased Donor-Derived Cell-Free DNA as a Predictor for the Early Detection of Antibody-Mediated Rejection Following Heart Transplantation / $c D. Dlouha, S. Chytilova, J. Vymetalova, E. Rohlova, M. Lukasova, S. Novakova, JA. Hubacek
520    9_
$a Plasma circulating donor-derived cell-free DNA (ddcfDNA) can be used to noninvasively monitor acute rejection of heart transplants (HTx). This study utilized digital droplet PCR to analyze ddcfDNA concentrations (measured in copies per milliliter) and the fractional abundance (%ddcfDNA) to differentiate between donor and recipient DNA on the basis of single nucleotide polymorphism (SNP) homozygosity. Seventy-seven patients participated in a study, providing 300 plasma samples. Both markers, mean ddcfDNA (cp/mL) and %ddcfDNA, showed similar decreasing trends following the HTx, (R2 < 0.2; p < 0.001). Significantly higher levels of ddcfDNA (cp/mL) and %ddcfDNA were observed during episodes of acute rejection (AR) compared to non-rejection samples (p < 0.001). Additionally, antibody-mediated rejection (AMR) was associated with increased %ddcfDNA levels compared to non-rejection and to acute cellular rejection samples (p < 0.001 and p < 0.01). A logistic regression model identified %ddcfDNA as an early predictor of AMR risk 10-19 days post-heart transplant (odds ratio 158, p < 0.02). Performance analysis established an optimal %ddcfDNA threshold of 0.125% for AMR detection, correctly identifying all patients without subsequent AMR. These findings suggest that early %ddcfDNA measurements post-HTx can accurately identify individuals unlikely to develop AMR during the first posttransplant year.
650    _2
$a lidé $7 D006801
650    12
$a transplantace srdce $x škodlivé účinky $7 D016027
650    12
$a rejekce štěpu $x diagnóza $x etiologie $x krev $7 D006084
650    12
$a volné cirkulující nukleové kyseliny $x krev $x genetika $7 D000073888
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a dárci tkání $7 D014019
650    _2
$a následné studie $7 D005500
650    _2
$a prognóza $7 D011379
650    12
$a biologické markery $x krev $7 D015415
650    _2
$a dospělí $7 D000328
650    _2
$a přežívání štěpu $7 D006085
650    12
$a isoprotilátky $x imunologie $7 D007518
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časná diagnóza $7 D042241
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chytilova, Sarka $u Department of Data Science, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Vymetalova, Jevgenija $u Cardio Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Rohlova, Eva $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Lukasova, Marianna $u Cardio Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Novakova, Sarka $u Experimental Medicine Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Hubacek, Jaroslav Alois $u Experimental Medicine Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000165371353
773    0_
$w MED00001167 $t Clinical transplantation $x 1399-0012 $g Roč. 39, č. 6 (2025), s. e70209
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40478999 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090942 $b ABA008
999    __
$a ok $b bmc $g 2366316 $s 1252533
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 39 $c 6 $d e70209 $e - $i 1399-0012 $m Clinical transplantation $n Clin Transplant $x MED00001167
GRA    __
$a NU20-06-00061 $p the Ministry of Health of the Czech Republic
GRA    __
$p the Ministry of Health of the Czech Republic-DRO
GRA    __
$a IN 00023001 $p Institute for Clinical and Experimental Medicine-IKEM
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace